explore -WSS

explore

author：fashion 2025-10-02 00:52:22 - browse：23964

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Obesity now affects over 1 billion people worldwide, study finds

WSS

FogPharma raises $145 million in rare Series E round

Listen: Wegovy in the brain & pivotal Alzheimer's data

Google and Epic fight stronger regulation of AI in health care

Custom gene therapy hints at new path for rare disease treatments

How dance can help nurses traumatized by Covid

Flu vaccine offering decent levels of protection this winter, new data show

hotspot

explore

knowledge

Psychedelics group wrestles with new pharma identity

Why getting cancer drugs just got harder for rural patients

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Virtual Event: The State of Biosimilars: What to Watch

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Heart attack and stroke risk calculators need revising

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

focus

FDA approves RSV monoclonal antibody for infants, toddlers

RaDonda Vaught to speak at CommonSpirit event on patient safety

Pfizer highlights cancer drugs it thinks could reignite investor interest

Clinical trials giant ICON acquires HumanFirst

Why hospitals are withdrawing from US News rankings

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

entertainment

hotspot

explore

focus